These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32798648)

  • 1. The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis.
    He Y; Huang Y; Mai C; Pan H; Luo HB; Liu L; Xie Y
    Pharmacol Res; 2020 Nov; 161():105134. PubMed ID: 32798648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One year in review: novelties in the treatment of rheumatoid arthritis.
    Guidelli GM; Barskova T; Brizi MG; Lepri G; Parma A; Talarico R; Cantarini L; Frediani B
    Clin Exp Rheumatol; 2015; 33(1):102-8. PubMed ID: 25719499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis.
    Azizi G; Jadidi-Niaragh F; Mirshafiey A
    Int J Rheum Dis; 2013 Jun; 16(3):243-53. PubMed ID: 23981743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanistic insight of phytoestrogens used for Rheumatoid arthritis: An evidence-based review.
    Chakraborty D; Gupta K; Biswas S
    Biomed Pharmacother; 2021 Jan; 133():111039. PubMed ID: 33254019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
    Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
    Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycolysis Rate-Limiting Enzymes: Novel Potential Regulators of Rheumatoid Arthritis Pathogenesis.
    Zuo J; Tang J; Lu M; Zhou Z; Li Y; Tian H; Liu E; Gao B; Liu T; Shao P
    Front Immunol; 2021; 12():779787. PubMed ID: 34899740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction.
    Boissier MC; Semerano L; Challal S; Saidenberg-Kermanac'h N; Falgarone G
    J Autoimmun; 2012 Sep; 39(3):222-8. PubMed ID: 22704962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
    Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
    J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms].
    Wollheim FA
    Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990
    [No Abstract]   [Full Text] [Related]  

  • 10. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies.
    Itoh Y
    Prog Mol Biol Transl Sci; 2017; 148():327-338. PubMed ID: 28662826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic compounds from traditional Chinese medicine targeting endoplasmic reticulum stress to alleviate rheumatoid arthritis.
    de Seabra Rodrigues Dias IR; Lo HH; Zhang K; Law BYK; Nasim AA; Chung SK; Wong VKW; Liu L
    Pharmacol Res; 2021 Aug; 170():105696. PubMed ID: 34052360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year in review 2016: pathogenesis of rheumatoid arthritis.
    Bellucci E; Terenzi R; La Paglia GM; Gentileschi S; Tripoli A; Tani C; Alunno A
    Clin Exp Rheumatol; 2016; 34(5):793-801. PubMed ID: 27716458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S; Mohanty M; Padhan P
    Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptors conserve the therapeutic target potential for the treatment of rheumatoid arthritis.
    Mai CT; Zheng DC; Li XZ; Zhou H; Xie Y
    Pharmacol Res; 2021 Aug; 170():105747. PubMed ID: 34186192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3',5'-cAMP phosphodiesterase inhibitors in the combined treatment of patients with rheumatoid arthritis].
    Bakaliuk OI; Shved MI; Hrebenyk MV
    Lik Sprava; 1998 Aug; (6):34-7. PubMed ID: 9844866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis: inflammation and bone loss.
    Schett G
    Wien Med Wochenschr; 2006 Jan; 156(1-2):34-41. PubMed ID: 16465612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New biologics for rheumatoid arthritis.
    Choy E
    J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence.
    Wen RT; Liang JH; Zhang HT
    Adv Neurobiol; 2017; 17():413-444. PubMed ID: 28956341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.